Jessica Tassan
Stock Analyst at Piper Sandler
(1.02)
# 3,897
Out of 5,154 analysts
86
Total ratings
28.77%
Success rate
-14.46%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Jessica Tassan
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| CI The Cigna Group | Reiterates: Overweight | $374 → $370 | $271.63 | +36.21% | 5 | Mar 3, 2026 | |
| TDOC Teladoc Health | Reiterates: Overweight | $12 → $9 | $5.08 | +77.17% | 7 | Feb 26, 2026 | |
| DOCS Doximity | Maintains: Overweight | $40 → $42 | $25.34 | +65.75% | 6 | Feb 20, 2026 | |
| OMCL Omnicell | Reiterates: Overweight | $63 → $49 | $41.30 | +18.64% | 5 | Feb 6, 2026 | |
| HNGE Hinge Health | Maintains: Overweight | $71 → $60 | $46.14 | +30.04% | 3 | Jan 9, 2026 | |
| ALHC Alignment Healthcare | Maintains: Overweight | $20 → $30 | $18.44 | +62.69% | 6 | Jan 6, 2026 | |
| CVS CVS Health | Reiterates: Overweight | $99 → $101 | $77.92 | +29.62% | 6 | Dec 10, 2025 | |
| OSCR Oscar Health | Upgrades: Overweight | $13 → $25 | $13.84 | +80.64% | 7 | Nov 26, 2025 | |
| UNH UnitedHealth Group | Maintains: Overweight | $423 → $417 | $286.48 | +45.56% | 9 | Oct 29, 2025 | |
| PHR Phreesia | Maintains: Overweight | $33 → $34 | $12.05 | +182.16% | 6 | Sep 5, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $16 → $18 | $3.17 | +467.82% | 4 | Aug 28, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $8 → $4 | $1.95 | +105.13% | 12 | Aug 27, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $44 → $86 | $17.21 | +399.71% | 3 | Aug 15, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $288 → $272 | $179.15 | +51.83% | 4 | Jul 31, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Neutral | $10 → $8 | $5.46 | +46.52% | 3 | May 23, 2025 |
The Cigna Group
Mar 3, 2026
Reiterates: Overweight
Price Target: $374 → $370
Current: $271.63
Upside: +36.21%
Teladoc Health
Feb 26, 2026
Reiterates: Overweight
Price Target: $12 → $9
Current: $5.08
Upside: +77.17%
Doximity
Feb 20, 2026
Maintains: Overweight
Price Target: $40 → $42
Current: $25.34
Upside: +65.75%
Omnicell
Feb 6, 2026
Reiterates: Overweight
Price Target: $63 → $49
Current: $41.30
Upside: +18.64%
Hinge Health
Jan 9, 2026
Maintains: Overweight
Price Target: $71 → $60
Current: $46.14
Upside: +30.04%
Alignment Healthcare
Jan 6, 2026
Maintains: Overweight
Price Target: $20 → $30
Current: $18.44
Upside: +62.69%
CVS Health
Dec 10, 2025
Reiterates: Overweight
Price Target: $99 → $101
Current: $77.92
Upside: +29.62%
Oscar Health
Nov 26, 2025
Upgrades: Overweight
Price Target: $13 → $25
Current: $13.84
Upside: +80.64%
UnitedHealth Group
Oct 29, 2025
Maintains: Overweight
Price Target: $423 → $417
Current: $286.48
Upside: +45.56%
Phreesia
Sep 5, 2025
Maintains: Overweight
Price Target: $33 → $34
Current: $12.05
Upside: +182.16%
Aug 28, 2025
Maintains: Overweight
Price Target: $16 → $18
Current: $3.17
Upside: +467.82%
Aug 27, 2025
Downgrades: Neutral
Price Target: $8 → $4
Current: $1.95
Upside: +105.13%
Aug 15, 2025
Maintains: Overweight
Price Target: $44 → $86
Current: $17.21
Upside: +399.71%
Jul 31, 2025
Maintains: Neutral
Price Target: $288 → $272
Current: $179.15
Upside: +51.83%
May 23, 2025
Reiterates: Neutral
Price Target: $10 → $8
Current: $5.46
Upside: +46.52%